Evaluation of Thrombocytopenia

Initial Diagnostic Approach

The American Society of Hematology suggests that mild thrombocytopenia is generally asymptomatic, with a platelet count of 50,000-150,000/μL, and typically requires no treatment 1
Evaluate for active bleeding, including mucosal bleeding, gastrointestinal bleeding, hematuria, or intracranial hemorrhage, as recommended by the American Society of Hematology 2

Pregnancy status should be assessed, as gestational thrombocytopenia, preeclampsia, and HELLP syndrome can occur, according to the American College of Obstetricians and Gynecologists 3

HIV testing is recommended in patients with risk factors, as suggested by the Centers for Disease Control and Prevention 3
The American Society of Hematology recommends that a direct antiglobulin test (DAT) and reticulocyte count be performed if hemolysis is suspected 2

For patients with a platelet count >50,000/μL, no treatment is required in the absence of bleeding or planned invasive procedures, as recommended by the American Society of Hematology 2, 1
The American Society of Hematology suggests that treatment is indicated only if active bleeding is present for patients with a platelet count of 20,000-50,000/μL 2
For patients with a platelet count <10,000/μL, high-risk bleeding treatment is mandatory, and all anticoagulation should be discontinued temporarily, as recommended by the American Society of Hematology 6

In pregnant women with thrombocytopenia, no treatment is required if the platelet count is >50,000/μL without bleeding, according to the American College of Obstetricians and Gynecologists 3
For children with ITP, observation is appropriate for most cases without significant bleeding, as approximately two-thirds improve spontaneously, as suggested by the American Society of Hematology 5, 7
The American Society of Hematology recommends that the target platelet count in ITP should be ≥50,000/μL to reduce bleeding risk, rather than attempting to normalize platelet counts 2

Immediate emergency department referral is indicated if the patient is acutely unwell, has active significant bleeding, or is experiencing a rapid platelet decline, as recommended by the American Society of Hematology 1